Integrins, transmembrane proteins that bind the extracellular matrix (ECM), are heterodimers composed of distinct a and b subunits. Vertebrates make a variety of a and bsubunits, with each b subunit capable of pairing with several different asubtypes to produce heterodimers with distinct ligand binding and cell signaling functions. The complexity of the vertebrate integrin repertoire complicates the analysis of in vivo integrin function. C. elegans expresses a limited set of integrins, allowing for analysis of the functional significance of different integrin isoforms in vivo. To date, only two C. elegans a integrin subunits have been identified: PAT-2 and INA-1. These subunits are expressed in different tissues, both pairing with a single b subunit, PAT-3. aINA-1 bPAT-3 heterodimers are expressed in a variety of cells, including neurons, where they function in migration and axon fasciculation. In contrast, the aPAT-2 bPAT-3 heterodimer is expressed in muscle and myoepithelial cells, localizing to adhesion structures attaching body wall muscle cells to the hypodermis. Both
pat-2 and
pat-3 loss-of-function mutations block the assembly of anchorage structures and the associated contractile apparatus. To ask if the PAT-2 subunit of muscle integrins performs unique, cell-specific functions required for muscle development, we are assessing the ability of INA-1 to replace PAT-2 during muscle development. By transforming wild-type worms with a functional
ina-1::gfp fusion (provided by Baum and Garriga) driven by the endogenous
pat-2 promoter, we have shown muscle cells are capable of assembling an aINA-1 bPAT-3 heterodimer. This heterodimer is expressed on the surface of body wall muscles and localizes to both dense bodies and M lines, the sites of normal aPAT-2 bPAT-3 localization. Although localized properly, aINA-1 bPAT-3 has dominant effects on adhesion structure assembly, indicated by occasional spontaneous detachment of the myofilament lattice from the body wall. Localization of aINA-1 bPAT-3 heterodimers to dense bodies and M lines suggests this integrin heterodimer is, at least, partially functional in body wall muscle and is can bind to ECM and/or cytoplasmic proteins that direct it to nascent attachment structures. With evidence aINA-1 bPAT-3 functions at least partially in muscle cells, we looked to see if the heterodimer could rescue muscle development in
pat-2 loss-of-function mutants.
pat-2 mutants are characterized by the failure to assemble muscle cytoskeleton, which causes complete embryonic paralysis. INA-1 partially rescued muscle activity, but did not support complete myofilament lattice organization. These results provide further evidence INA-1 is partially functional in the muscle cell, but also suggest the PAT-2 subunit performs specialized functions necessary for the normal muscle cell developmental program. Currently, we are constructing chimeras between INA-1 and PAT-2 to determine whether these specializations map to the extracellular and/or cytoplasmic domains of PAT-2.